Loganin attenuates neuroinflammation after ischemic stroke and fracture by regulating α7nAChR‐mediated microglial polarization

Fracture in acute stage of ischemic stroke can increase inflammatory response and enhance stroke injury. Loganin alleviates the symptoms of many inflammatory diseases through its anti‐inflammatory effect, but its role in ischemic stroke and fracture remains to be explored. Here, mice were handled wi...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Environmental toxicology 2023-03, Vol.38 (4), p.926-940
Hauptverfasser: Huo, Kang, Xu, Jing, Ma, Kaige, Wang, Jianyi, Wei, Meng, Zhang, Meng, Guo, Qinyue, Qu, Qiumin
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 940
container_issue 4
container_start_page 926
container_title Environmental toxicology
container_volume 38
creator Huo, Kang
Xu, Jing
Ma, Kaige
Wang, Jianyi
Wei, Meng
Zhang, Meng
Guo, Qinyue
Qu, Qiumin
description Fracture in acute stage of ischemic stroke can increase inflammatory response and enhance stroke injury. Loganin alleviates the symptoms of many inflammatory diseases through its anti‐inflammatory effect, but its role in ischemic stroke and fracture remains to be explored. Here, mice were handled with permanent middle cerebral artery occlusion (pMCAO) followed by tibial fracture 1 day later to establish a pMCAO+fracture model. Loganin or Methyllycaconitine (MLA, a specific a7nAchR inhibitor) were intragastrically administered 2 or 0.5 h before pMCAO, respectively. And mouse motor function and infarct volume were evaluated 3 days after pMCAO. We found that loganin alleviated the neurological deficit, cerebral infarction volume, and neuronal apoptosis (NeuN+TUNEL+) in mice with pMCAO+fracture. And loganin suppressed pMCAO+fracture‐induced neuroinflammation by promoting M2 microglia polarization (Iba1+CD206+) and inhibiting M1 microglia polarization (Iba1+CD11b+). While administration with MLA reversed the protective effect of loganin on pMCAO+fracture‐induced neurological deficit and neuroinflammation. Next, LPS was used to stimulate BV2 microglia to simulate pMCAO+fracture‐induced inflammatory microenvironment in vitro. Loganin facilitated the transformation of LPS‐stimulated BV2 cells from M1 pro‐inflammatory state (CD11b+) to M2 anti‐inflammatory state (CD206+), which was antagonized by treatment with MLA. And loganin induced autophagy activation in LPS‐stimulated BV2 cells by activating a7nAchR. Moreover, treatment with rapamycin (an autophagy activator) neutralized the inhibitory effect of MLA on loganin induced transformation of BV2 cells to M2 phenotype. Furthermore, BV2 cells were treated with LPS, LPS + loganin, LPS + loganin+MLA, or LPS + loganin+MLA+ rapamycin to obtain conditioned medium (CM) for stimulating primary neurons. Loganin reduced the damage of primary neurons caused by LPS‐stimulated BV2 microglia through activating a7nAchR and inducing autophagy activation. In conclusion, loganin played anti‐inflammatory and neuroprotective roles in pMCAO + fracture mice by activating a7nAchR, enhancing autophagy and promoting M2 polarization of microglia.
doi_str_mv 10.1002/tox.23738
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2765775785</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2785182583</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3538-6c6652ce568946485f860a282eb0959a6e6fde8bead927aee618374fb2736d563</originalsourceid><addsrcrecordid>eNp1kUtOHDEQhq0IFAjJIhdAlrIhiwa3PX70Eo3CQxoJCREpu5a7u3owcduD7RYZVnCDXCUX4RCcBDMDLCKxckn-6lNV_Qh9Lcl-SQg9SP7PPmWSqQ9ou-SUFpJKtbGqSTEhqtxCn2K8IoRUgouPaIsJwWTJyTa6n_m5dsZhnRK4USeI2MEYvHG91cOgk_H5s08QsIntJQymxTEF_xuwdh3ug27TGAA3SxxgPtrc4Ob44Z90h9PL88e7vwN0Jms7nDuDn1ujLV54q4O5Xck_o81e2whfXt4d9PPox8X0pJidHZ9OD2dFyzhThWiF4LQFLlQ1ERPFeyWIpopCQypeaQGi70A1oLuKSg0gSsXkpG-oZKLjgu2gvbV3Efz1CDHVQ14IrNUO_BhrKgWXkkvFM_rtP_TKj8Hl6TKleKkoVyxT39dUXivGAH29CGbQYVmXpH7Opc651KtcMrv7YhybfJA38jWIDBysgRtjYfm-qb44-7VWPgEQkJst</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2785182583</pqid></control><display><type>article</type><title>Loganin attenuates neuroinflammation after ischemic stroke and fracture by regulating α7nAChR‐mediated microglial polarization</title><source>MEDLINE</source><source>Wiley Journals</source><creator>Huo, Kang ; Xu, Jing ; Ma, Kaige ; Wang, Jianyi ; Wei, Meng ; Zhang, Meng ; Guo, Qinyue ; Qu, Qiumin</creator><creatorcontrib>Huo, Kang ; Xu, Jing ; Ma, Kaige ; Wang, Jianyi ; Wei, Meng ; Zhang, Meng ; Guo, Qinyue ; Qu, Qiumin</creatorcontrib><description>Fracture in acute stage of ischemic stroke can increase inflammatory response and enhance stroke injury. Loganin alleviates the symptoms of many inflammatory diseases through its anti‐inflammatory effect, but its role in ischemic stroke and fracture remains to be explored. Here, mice were handled with permanent middle cerebral artery occlusion (pMCAO) followed by tibial fracture 1 day later to establish a pMCAO+fracture model. Loganin or Methyllycaconitine (MLA, a specific a7nAchR inhibitor) were intragastrically administered 2 or 0.5 h before pMCAO, respectively. And mouse motor function and infarct volume were evaluated 3 days after pMCAO. We found that loganin alleviated the neurological deficit, cerebral infarction volume, and neuronal apoptosis (NeuN+TUNEL+) in mice with pMCAO+fracture. And loganin suppressed pMCAO+fracture‐induced neuroinflammation by promoting M2 microglia polarization (Iba1+CD206+) and inhibiting M1 microglia polarization (Iba1+CD11b+). While administration with MLA reversed the protective effect of loganin on pMCAO+fracture‐induced neurological deficit and neuroinflammation. Next, LPS was used to stimulate BV2 microglia to simulate pMCAO+fracture‐induced inflammatory microenvironment in vitro. Loganin facilitated the transformation of LPS‐stimulated BV2 cells from M1 pro‐inflammatory state (CD11b+) to M2 anti‐inflammatory state (CD206+), which was antagonized by treatment with MLA. And loganin induced autophagy activation in LPS‐stimulated BV2 cells by activating a7nAchR. Moreover, treatment with rapamycin (an autophagy activator) neutralized the inhibitory effect of MLA on loganin induced transformation of BV2 cells to M2 phenotype. Furthermore, BV2 cells were treated with LPS, LPS + loganin, LPS + loganin+MLA, or LPS + loganin+MLA+ rapamycin to obtain conditioned medium (CM) for stimulating primary neurons. Loganin reduced the damage of primary neurons caused by LPS‐stimulated BV2 microglia through activating a7nAchR and inducing autophagy activation. In conclusion, loganin played anti‐inflammatory and neuroprotective roles in pMCAO + fracture mice by activating a7nAchR, enhancing autophagy and promoting M2 polarization of microglia.</description><identifier>ISSN: 1520-4081</identifier><identifier>EISSN: 1522-7278</identifier><identifier>DOI: 10.1002/tox.23738</identifier><identifier>PMID: 36637150</identifier><language>eng</language><publisher>Hoboken, USA: John Wiley &amp; Sons, Inc</publisher><subject>alpha7 Nicotinic Acetylcholine Receptor ; Animals ; Anti-Inflammatory Agents - pharmacology ; Apoptosis ; Autophagy ; CD11b antigen ; Cells ; Cerebral blood flow ; Cerebral infarction ; Genetic transformation ; Inflammatory diseases ; Inflammatory response ; Ischemia ; Ischemic Stroke ; Lipopolysaccharides ; Lipopolysaccharides - pharmacology ; loganin ; Methyllycaconitine ; Mice ; Microglia ; microglia polarization ; Neuroinflammatory Diseases ; Neurons ; Neuroprotection ; Occlusion ; permanent middle cerebral artery occlusion + fracture ; Phenotypes ; Polarization ; Rapamycin ; Signs and symptoms ; Stroke ; Symptoms ; α7nAChR</subject><ispartof>Environmental toxicology, 2023-03, Vol.38 (4), p.926-940</ispartof><rights>2023 Wiley Periodicals LLC.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3538-6c6652ce568946485f860a282eb0959a6e6fde8bead927aee618374fb2736d563</citedby><cites>FETCH-LOGICAL-c3538-6c6652ce568946485f860a282eb0959a6e6fde8bead927aee618374fb2736d563</cites><orcidid>0000-0002-6416-6961</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Ftox.23738$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Ftox.23738$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,780,784,1417,27924,27925,45574,45575</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/36637150$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Huo, Kang</creatorcontrib><creatorcontrib>Xu, Jing</creatorcontrib><creatorcontrib>Ma, Kaige</creatorcontrib><creatorcontrib>Wang, Jianyi</creatorcontrib><creatorcontrib>Wei, Meng</creatorcontrib><creatorcontrib>Zhang, Meng</creatorcontrib><creatorcontrib>Guo, Qinyue</creatorcontrib><creatorcontrib>Qu, Qiumin</creatorcontrib><title>Loganin attenuates neuroinflammation after ischemic stroke and fracture by regulating α7nAChR‐mediated microglial polarization</title><title>Environmental toxicology</title><addtitle>Environ Toxicol</addtitle><description>Fracture in acute stage of ischemic stroke can increase inflammatory response and enhance stroke injury. Loganin alleviates the symptoms of many inflammatory diseases through its anti‐inflammatory effect, but its role in ischemic stroke and fracture remains to be explored. Here, mice were handled with permanent middle cerebral artery occlusion (pMCAO) followed by tibial fracture 1 day later to establish a pMCAO+fracture model. Loganin or Methyllycaconitine (MLA, a specific a7nAchR inhibitor) were intragastrically administered 2 or 0.5 h before pMCAO, respectively. And mouse motor function and infarct volume were evaluated 3 days after pMCAO. We found that loganin alleviated the neurological deficit, cerebral infarction volume, and neuronal apoptosis (NeuN+TUNEL+) in mice with pMCAO+fracture. And loganin suppressed pMCAO+fracture‐induced neuroinflammation by promoting M2 microglia polarization (Iba1+CD206+) and inhibiting M1 microglia polarization (Iba1+CD11b+). While administration with MLA reversed the protective effect of loganin on pMCAO+fracture‐induced neurological deficit and neuroinflammation. Next, LPS was used to stimulate BV2 microglia to simulate pMCAO+fracture‐induced inflammatory microenvironment in vitro. Loganin facilitated the transformation of LPS‐stimulated BV2 cells from M1 pro‐inflammatory state (CD11b+) to M2 anti‐inflammatory state (CD206+), which was antagonized by treatment with MLA. And loganin induced autophagy activation in LPS‐stimulated BV2 cells by activating a7nAchR. Moreover, treatment with rapamycin (an autophagy activator) neutralized the inhibitory effect of MLA on loganin induced transformation of BV2 cells to M2 phenotype. Furthermore, BV2 cells were treated with LPS, LPS + loganin, LPS + loganin+MLA, or LPS + loganin+MLA+ rapamycin to obtain conditioned medium (CM) for stimulating primary neurons. Loganin reduced the damage of primary neurons caused by LPS‐stimulated BV2 microglia through activating a7nAchR and inducing autophagy activation. In conclusion, loganin played anti‐inflammatory and neuroprotective roles in pMCAO + fracture mice by activating a7nAchR, enhancing autophagy and promoting M2 polarization of microglia.</description><subject>alpha7 Nicotinic Acetylcholine Receptor</subject><subject>Animals</subject><subject>Anti-Inflammatory Agents - pharmacology</subject><subject>Apoptosis</subject><subject>Autophagy</subject><subject>CD11b antigen</subject><subject>Cells</subject><subject>Cerebral blood flow</subject><subject>Cerebral infarction</subject><subject>Genetic transformation</subject><subject>Inflammatory diseases</subject><subject>Inflammatory response</subject><subject>Ischemia</subject><subject>Ischemic Stroke</subject><subject>Lipopolysaccharides</subject><subject>Lipopolysaccharides - pharmacology</subject><subject>loganin</subject><subject>Methyllycaconitine</subject><subject>Mice</subject><subject>Microglia</subject><subject>microglia polarization</subject><subject>Neuroinflammatory Diseases</subject><subject>Neurons</subject><subject>Neuroprotection</subject><subject>Occlusion</subject><subject>permanent middle cerebral artery occlusion + fracture</subject><subject>Phenotypes</subject><subject>Polarization</subject><subject>Rapamycin</subject><subject>Signs and symptoms</subject><subject>Stroke</subject><subject>Symptoms</subject><subject>α7nAChR</subject><issn>1520-4081</issn><issn>1522-7278</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kUtOHDEQhq0IFAjJIhdAlrIhiwa3PX70Eo3CQxoJCREpu5a7u3owcduD7RYZVnCDXCUX4RCcBDMDLCKxckn-6lNV_Qh9Lcl-SQg9SP7PPmWSqQ9ou-SUFpJKtbGqSTEhqtxCn2K8IoRUgouPaIsJwWTJyTa6n_m5dsZhnRK4USeI2MEYvHG91cOgk_H5s08QsIntJQymxTEF_xuwdh3ug27TGAA3SxxgPtrc4Ob44Z90h9PL88e7vwN0Jms7nDuDn1ujLV54q4O5Xck_o81e2whfXt4d9PPox8X0pJidHZ9OD2dFyzhThWiF4LQFLlQ1ERPFeyWIpopCQypeaQGi70A1oLuKSg0gSsXkpG-oZKLjgu2gvbV3Efz1CDHVQ14IrNUO_BhrKgWXkkvFM_rtP_TKj8Hl6TKleKkoVyxT39dUXivGAH29CGbQYVmXpH7Opc651KtcMrv7YhybfJA38jWIDBysgRtjYfm-qb44-7VWPgEQkJst</recordid><startdate>202303</startdate><enddate>202303</enddate><creator>Huo, Kang</creator><creator>Xu, Jing</creator><creator>Ma, Kaige</creator><creator>Wang, Jianyi</creator><creator>Wei, Meng</creator><creator>Zhang, Meng</creator><creator>Guo, Qinyue</creator><creator>Qu, Qiumin</creator><general>John Wiley &amp; Sons, Inc</general><general>Wiley Subscription Services, Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QH</scope><scope>7ST</scope><scope>7TN</scope><scope>7U7</scope><scope>7UA</scope><scope>C1K</scope><scope>F1W</scope><scope>H97</scope><scope>K9.</scope><scope>L.G</scope><scope>M7N</scope><scope>SOI</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-6416-6961</orcidid></search><sort><creationdate>202303</creationdate><title>Loganin attenuates neuroinflammation after ischemic stroke and fracture by regulating α7nAChR‐mediated microglial polarization</title><author>Huo, Kang ; Xu, Jing ; Ma, Kaige ; Wang, Jianyi ; Wei, Meng ; Zhang, Meng ; Guo, Qinyue ; Qu, Qiumin</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3538-6c6652ce568946485f860a282eb0959a6e6fde8bead927aee618374fb2736d563</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>alpha7 Nicotinic Acetylcholine Receptor</topic><topic>Animals</topic><topic>Anti-Inflammatory Agents - pharmacology</topic><topic>Apoptosis</topic><topic>Autophagy</topic><topic>CD11b antigen</topic><topic>Cells</topic><topic>Cerebral blood flow</topic><topic>Cerebral infarction</topic><topic>Genetic transformation</topic><topic>Inflammatory diseases</topic><topic>Inflammatory response</topic><topic>Ischemia</topic><topic>Ischemic Stroke</topic><topic>Lipopolysaccharides</topic><topic>Lipopolysaccharides - pharmacology</topic><topic>loganin</topic><topic>Methyllycaconitine</topic><topic>Mice</topic><topic>Microglia</topic><topic>microglia polarization</topic><topic>Neuroinflammatory Diseases</topic><topic>Neurons</topic><topic>Neuroprotection</topic><topic>Occlusion</topic><topic>permanent middle cerebral artery occlusion + fracture</topic><topic>Phenotypes</topic><topic>Polarization</topic><topic>Rapamycin</topic><topic>Signs and symptoms</topic><topic>Stroke</topic><topic>Symptoms</topic><topic>α7nAChR</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Huo, Kang</creatorcontrib><creatorcontrib>Xu, Jing</creatorcontrib><creatorcontrib>Ma, Kaige</creatorcontrib><creatorcontrib>Wang, Jianyi</creatorcontrib><creatorcontrib>Wei, Meng</creatorcontrib><creatorcontrib>Zhang, Meng</creatorcontrib><creatorcontrib>Guo, Qinyue</creatorcontrib><creatorcontrib>Qu, Qiumin</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Aqualine</collection><collection>Environment Abstracts</collection><collection>Oceanic Abstracts</collection><collection>Toxicology Abstracts</collection><collection>Water Resources Abstracts</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ASFA: Aquatic Sciences and Fisheries Abstracts</collection><collection>Aquatic Science &amp; Fisheries Abstracts (ASFA) 3: Aquatic Pollution &amp; Environmental Quality</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Aquatic Science &amp; Fisheries Abstracts (ASFA) Professional</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Environment Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Environmental toxicology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Huo, Kang</au><au>Xu, Jing</au><au>Ma, Kaige</au><au>Wang, Jianyi</au><au>Wei, Meng</au><au>Zhang, Meng</au><au>Guo, Qinyue</au><au>Qu, Qiumin</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Loganin attenuates neuroinflammation after ischemic stroke and fracture by regulating α7nAChR‐mediated microglial polarization</atitle><jtitle>Environmental toxicology</jtitle><addtitle>Environ Toxicol</addtitle><date>2023-03</date><risdate>2023</risdate><volume>38</volume><issue>4</issue><spage>926</spage><epage>940</epage><pages>926-940</pages><issn>1520-4081</issn><eissn>1522-7278</eissn><abstract>Fracture in acute stage of ischemic stroke can increase inflammatory response and enhance stroke injury. Loganin alleviates the symptoms of many inflammatory diseases through its anti‐inflammatory effect, but its role in ischemic stroke and fracture remains to be explored. Here, mice were handled with permanent middle cerebral artery occlusion (pMCAO) followed by tibial fracture 1 day later to establish a pMCAO+fracture model. Loganin or Methyllycaconitine (MLA, a specific a7nAchR inhibitor) were intragastrically administered 2 or 0.5 h before pMCAO, respectively. And mouse motor function and infarct volume were evaluated 3 days after pMCAO. We found that loganin alleviated the neurological deficit, cerebral infarction volume, and neuronal apoptosis (NeuN+TUNEL+) in mice with pMCAO+fracture. And loganin suppressed pMCAO+fracture‐induced neuroinflammation by promoting M2 microglia polarization (Iba1+CD206+) and inhibiting M1 microglia polarization (Iba1+CD11b+). While administration with MLA reversed the protective effect of loganin on pMCAO+fracture‐induced neurological deficit and neuroinflammation. Next, LPS was used to stimulate BV2 microglia to simulate pMCAO+fracture‐induced inflammatory microenvironment in vitro. Loganin facilitated the transformation of LPS‐stimulated BV2 cells from M1 pro‐inflammatory state (CD11b+) to M2 anti‐inflammatory state (CD206+), which was antagonized by treatment with MLA. And loganin induced autophagy activation in LPS‐stimulated BV2 cells by activating a7nAchR. Moreover, treatment with rapamycin (an autophagy activator) neutralized the inhibitory effect of MLA on loganin induced transformation of BV2 cells to M2 phenotype. Furthermore, BV2 cells were treated with LPS, LPS + loganin, LPS + loganin+MLA, or LPS + loganin+MLA+ rapamycin to obtain conditioned medium (CM) for stimulating primary neurons. Loganin reduced the damage of primary neurons caused by LPS‐stimulated BV2 microglia through activating a7nAchR and inducing autophagy activation. In conclusion, loganin played anti‐inflammatory and neuroprotective roles in pMCAO + fracture mice by activating a7nAchR, enhancing autophagy and promoting M2 polarization of microglia.</abstract><cop>Hoboken, USA</cop><pub>John Wiley &amp; Sons, Inc</pub><pmid>36637150</pmid><doi>10.1002/tox.23738</doi><tpages>15</tpages><orcidid>https://orcid.org/0000-0002-6416-6961</orcidid></addata></record>
fulltext fulltext
identifier ISSN: 1520-4081
ispartof Environmental toxicology, 2023-03, Vol.38 (4), p.926-940
issn 1520-4081
1522-7278
language eng
recordid cdi_proquest_miscellaneous_2765775785
source MEDLINE; Wiley Journals
subjects alpha7 Nicotinic Acetylcholine Receptor
Animals
Anti-Inflammatory Agents - pharmacology
Apoptosis
Autophagy
CD11b antigen
Cells
Cerebral blood flow
Cerebral infarction
Genetic transformation
Inflammatory diseases
Inflammatory response
Ischemia
Ischemic Stroke
Lipopolysaccharides
Lipopolysaccharides - pharmacology
loganin
Methyllycaconitine
Mice
Microglia
microglia polarization
Neuroinflammatory Diseases
Neurons
Neuroprotection
Occlusion
permanent middle cerebral artery occlusion + fracture
Phenotypes
Polarization
Rapamycin
Signs and symptoms
Stroke
Symptoms
α7nAChR
title Loganin attenuates neuroinflammation after ischemic stroke and fracture by regulating α7nAChR‐mediated microglial polarization
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-01T15%3A00%3A14IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Loganin%20attenuates%20neuroinflammation%20after%20ischemic%20stroke%20and%20fracture%20by%20regulating%20%CE%B17nAChR%E2%80%90mediated%20microglial%20polarization&rft.jtitle=Environmental%20toxicology&rft.au=Huo,%20Kang&rft.date=2023-03&rft.volume=38&rft.issue=4&rft.spage=926&rft.epage=940&rft.pages=926-940&rft.issn=1520-4081&rft.eissn=1522-7278&rft_id=info:doi/10.1002/tox.23738&rft_dat=%3Cproquest_cross%3E2785182583%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2785182583&rft_id=info:pmid/36637150&rfr_iscdi=true